Dr. Marc A. Rovito

Paul Celano is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Celano is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.

Meher Burki is a Hematologist and an Oncologist in Kennett Square, Pennsylvania. Dr. Burki is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Paget Disease of the Breast, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, and Bone Marrow Aspiration. Dr. Burki is currently accepting new patients.

Dr. Armstrong works primarily in the area of women's malignancies, with a particular emphasis on breast cancer, ovarian cancer and other gynecologic malignancies, and the genetics of breast and ovarian cancer. She directs the medical gynecologic oncology clinical service and oversees therapeutic clinical trials in gynecologic cancers. Dr. Armstrong's clinical focus is on the development of new therapeutic approaches to the treatment of breast cancer and gynecologic malignancies. Particular areas of interest are intraperitoneal therapy in ovarian cancer and targeted biologic therapies. Dr. Armstrong also directs the Kimmel Cancer Center's Breast and Ovarian Cancer Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examination of new strategies for cancer screening and prevention. Dr. Armstrong has lectured locally, nationally and internationally. She is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees and as chair of several clinical trials through this group. She is a representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute. Dr. Armstrong also serves as a representative of Johns Hopkins to the National Cooperative Cancer Network serving on the ovarian cancer and breast cancer risk reduction panels. She has participated as a member of the Cancer Working Group for the Office of Research on Women's Health for the National Institutes of Health, as a scientific reviewer for the breast and ovarian cancer research programs of the Department of Defense and the National Cancer Institute, as a reviewer for the NCI Special Emphasis Panel for Insight Awards to Stamp Out Breast Cancer and as a member of the NCI SPORE Program parent committee. Dr. Armstrong also is co-principal investigator for the NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site (LAPS) at Johns Hopkins, now the major avenue for adult oncology clinical trials in the country. Recent work includes immune checkpoint inhibitor therapy in endometrial cancers with microsatellite instability and PARP inhibition in ovarian cancer. Dr. Armstrong is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, and Ovarian Cancer.